Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Definium Therapeutics (NASDAQ:DFTX) through any online brokerage.
Other companies in Definium Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Definium Therapeutics has a consensus price target of $64.81.
The stock price for Definium Therapeutics (NASDAQ: DFTX) is $37.4 last updated October 9, 2026 at 7:04 PM EDT.
There are no upcoming dividends for Definium Therapeutics.
Definium Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Definium Therapeutics.
Definium Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.